---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-033718"
form_type: "8-K"
ticker: "MIRA"
cik: "0001904286"
company_name: "MIRA PHARMACEUTICALS, INC."
filed_at: "2024-08-23T23:59:59+00:00"
generated_at: "2026-05-31T07:53:55.214351+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MIRA Pharma reports 100% pain signal reversal with oral Ketamir-2 in rat neuropathic pain model

## Summary
- Low oral doses of Ketamir-2 reversed neuropathic pain for 14-22 days in nerve-ligation rat model.
- Highest dose achieved complete normalization of pain threshold, a 100% reversal of pain signal.
- Oral ketamine under same conditions showed no significant pain relief, highlighting Ketamir-2's superiority.
- Company plans further clinical development for Ketamir-2 as a transformative neuropathic pain treatment.

## SEC filing metadata
- accession: 0001493152-24-033718
- form_type: 8-K
- ticker: MIRA
- cik: 0001904286
- company_name: MIRA PHARMACEUTICALS, INC.
- filed_at: 2024-08-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1904286/000149315224033718/0001493152-24-033718-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1904286/000149315224033718/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-033718
- JSON: https://secwatch.observer/filing/0001493152-24-033718.json
- Plain text: https://secwatch.observer/filing/0001493152-24-033718.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.